Investors aiming to benefit from large price increases often use a method that combines fundamental soundness with opportune technical signs. The process involves looking for companies with solid basic growth—shown by high sales and earnings increases—while also keeping good financial condition and earnings. This basic groundwork is then combined with a positive technical situation, like a breakout formation, which hints the stock's price might be ready for its next rise. This dual method tries to find growth stocks that have good fundamentals and are also starting a period where market trends could increase their upward movement.
PTC Therapeutics Inc (NASDAQ:PTCT) offers an example for this investment method. The biopharmaceutical company, which works on rare diseases, displays signs of a good growth pattern while its stock chart shows a possible period of stability that might come before a breakout.
Fundamental Growth Pattern
The central part of the method is finding companies with increasing business speed. PTC Therapeutics' fundamental report shows a strong growth story. The company's revenue grew by 97.54% in the last year, while its Earnings Per Share (EPS) increased by a notable 277.07%. This is not limited to one quarter; the company has kept an average yearly revenue growth of 21.32% in recent years. Future expectations suggest this path will persist, with estimated yearly EPS growth of 25.49% and revenue growth of 17.10%. For a growth investor, these numbers are important as they show the company is effectively growing its marketed products for rare diseases like Duchenne muscular dystrophy and AADC deficiency.
Beyond just growth, the method needs "acceptable profitability and condition." PTC's fundamentals present a varied but getting better view in these parts:
- Profitability: The company has high margins, with a Gross Margin of 96.83% and an Operating Margin of 52.45%, doing better than most of its biotechnology industry. Its Return on Invested Capital (ROIC) of 41.48% is also high in the industry, showing good use of capital.
- Financial Condition: The company's ability to pay debts is good, with a Debt-to-Free-Cash-Flow ratio of 3.38, meaning it can manage its debts. Its current and quick ratios both show enough cash to cover short-term requirements.
You can see the complete details of this review in the detailed fundamental report for PTCT.
Technical Situation and Breakout Possibility
A good fundamental story is most effective when joined with a positive price chart. The technical review for PTCT indicates the stock is in a good place. The long-term direction is positive, with the stock price trading above its important moving averages (50-day, 100-day, and 200-day). More recently, the price has been moving sideways within a set area between about $73.44 and $80.20 over the last month. This kind of pause after a good upward move can sometimes be a base for the next rise.
Important technical points include:
- The stock is trading in the higher part of its 52-week range and has done better than 91% of the overall market in the past year.
- A recent "Pocket Pivot" signal has been seen, which is a volume-based sign hinting at buying by large investors.
- A price ceiling exists just above the current price in the $77.10-$77.61 area, while a price floor is set below near $75.64-$76.63. A clear move above the ceiling area could indicate the beginning of a new breakout period.
The technical analysis report gives PTCT a high score and mentions a good formation pattern, stating that prices have been moving sideways recently and could offer a chance.
Valuation Background
For growth investors, valuation requires balance. PTCT seems fairly priced compared to both its industry and the wider market. With a Price-to-Earnings (P/E) ratio of 10.59, it is valued lower than almost 98% of its biotechnology industry and below the S&P 500 average. Its Price-to-Free-Cash-Flow and Enterprise Value-to-EBITDA ratios also point to a fairly low valuation within its high-growth field. This fair valuation offers a buffer that is often missing in riskier growth investments.
Conclusion
PTC Therapeutics Inc represents the kind of stock sought by a combined growth-and-breakout method. The company shows very high past growth and good future estimates, backed by high profitability measures. At the same time, its stock chart displays a good long-term upward direction with a recent time of stability near a possible price ceiling—a typical formation watched by chart analysts for breakout signs. This combination of fundamental speed and technical placement makes PTCT a notable option for investors concentrated on growth.
This review came from a search made to find Strong Growth Stocks with good Technical Setup Ratings. If you want to look at other stocks that now fit similar conditions, you can use this search yourself here.
Disclaimer: This article is for information only and is not financial advice, a suggestion, or an offer or request to buy or sell any securities. The information given is based on supplied data and should not be the only reason for any investment choice. Investing has risks, including the possible loss of the original investment. Always do your own research and think about talking with a qualified financial advisor before making any investment choices.
